Quick Answer
Structure Therapeutics Inc. reported Net Income Loss of -$141.20 million for the year ending 2025.
- Structure Therapeutics Inc. showed a decrease of -15.2% in Net Income Loss from 2024 to 2025.
- This data is from Structure Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$13.08 million | Q2 2022: -$13.95 million | Q3 2022: -$12.42 million | Q1 2023: -$17.98 million | Q2 2023: -$23.28 million | Q3 2023: -$23.86 million | Q1 2024: -$26.04 million | Q2 2024: -$26.03 million | Q3 2024: -$33.98 million | Q1 2025: -$46.83 million | Q2 2025: -$61.66 million | Q3 2025: -$65.71 million.
- Over the full 4 years of available data (2022 to 2025), Structure Therapeutics Inc.'s Net Income Loss has declined by 175.1%.
- Historical annual values: Fiscal year 2025: -$141.20 million | Fiscal year 2024: -$122.53 million | Fiscal year 2023: -$89.62 million | Fiscal year 2022: -$51.32 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: